Hyloris Pharmaceuticals S.A.
BRU: HYL.BR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Brussels
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Jacobsen
- Employees
- 49
- Headquarters
- Liège, Belgium
- IPO year
- 2020
- Market cap
- €144.5M
- Website
- https://hyloris.com
Loading HYL…
Loading profile data…Frequently asked questions about HYL
What does Hyloris Pharmaceuticals S.A. (HYL.BR) do?
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive h...
Where does HYL.BR trade?
Hyloris Pharmaceuticals S.A. (HYL.BR) trades on the Euronext Brussels.
What sector is HYL.BR in?
Hyloris Pharmaceuticals S.A. (HYL.BR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hyloris Pharmaceuticals S.A.?
Thomas Jacobsen is the chief executive officer of Hyloris Pharmaceuticals S.A. (HYL.BR).
Where is Hyloris Pharmaceuticals S.A. headquartered?
Hyloris Pharmaceuticals S.A. is headquartered in Belgium.
Does HYL.BR pay a dividend?
Hyloris Pharmaceuticals S.A. (HYL.BR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HYL.BR go public?
Hyloris Pharmaceuticals S.A. (HYL.BR) completed its initial public offering in 2020.